Fractyl Health Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$105.7MTTM through 30 Jun 2026
Free Cash Flow -$83MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-116.1%ROA
Balance Sheet Health
Debt / Equity3.23x
Current Ratio4.78x
Net Debt-$51Mnet cash position
Cash & Equivalents$47.1M
Quality Metrics
Altman Z-Score-12.11
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2025: $0
Diluted EPS-$0.91TTMFY2025: $-1.86
Dividend
No dividend
Capital Allocation
R&D Spend$63.4M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Revita | $0 | View detailsTopline 6-month randomized data expected in early Q4 2026; potential FDA De Novo marketing application submission expected in late Q4 2026. | |
| Rejuva | $0 | View detailsFirst-in-human dosing anticipated in the second half of 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.